|
시장보고서
상품코드
2032526
시판 후 약물감시 및 의료 정보 시장 보고서 : 유형, 제품 유형, 최종 사용자, 지역별(2026-2034년)Post-marketing Pharmacovigilance and Medical Information Market Report by Type, Product, End User, and Region 2026-2034 |
||||||
세계의 시판 후 약물감시 및 의료 정보 시장 규모는 2025년에 67억 달러에 이르렀습니다. 향후 IMARC Group은 2034년까지 시장 규모가 145억 달러에 이르고, 2026-2034년 CAGR 8.68%를 나타낼 것으로 예측했습니다.
시판 후 약물감시 및 의료정보는 의약품이나 의료기기가 출시된 후 그 안전성과 유효성을 모니터링하는 활동을 말합니다. 여기에는 신약, 의료기기 및 치료법의 부작용 수집, 모니터링 및 예방이 포함됩니다. 이를 통해 이익과 관련된 위험을 명확히 하고, 잘못된 적응증을 부정함으로써 환자를 불필요한 위험으로부터 보호할 수 있습니다. 또한, 이는 연구자가 의약품 개발 주기 전반에 걸쳐 필요한 조치를 결정하는 데 도움이 됩니다. 그 결과, 시판 후 약물감시 및 의료정보는 환자와 의료인 사이에 제공되는 정보의 정확성을 평가하는 데 있어 헬스케어 산업에서 중요한 역할을 하고 있습니다. 또한, 연구기관에서 의약품의 안전성 가이드라인을 규제하는 데에도 활용되고 있습니다.
시판 후 약물감시 및 의료 정보 시장 동향 :
세계 고령화 진행과 당뇨병, 고혈압, 치매, 심혈관 질환, 골다공증 등 다양한 만성질환의 발생률 증가는 의약품 소비를 증가시키는 주요 요인 중 하나입니다. 또한, 생활습관병, 호흡기 및 심혈관계 감염, 신경계 및 종양성 질환의 발생 빈도가 증가함에 따라 전 세계 의약품 판매량이 증가하고 있습니다. 이로 인해 시장 전망은 매우 밝습니다. 이에 따라 의약품 부작용(ADR) 발생률 증가와 더불어, 첨단 ADR 보고 도구의 도입이 진행되면서 시장 성장을 견인하고 있습니다. 이와는 별도로 병원, 진료소, 검사 기관 및 의학 연구센터의 확장은 전 세계적으로 의약품 및 의료기기에 대한 수요를 촉진하고 있습니다. 또한, 각국 정부는 의료 인프라 및 의약품 안전성 모니터링 서비스 개선, 의료 데이터베이스의 유지 관리를 위한 다양한 노력을 기울이고 있으며, 이는 시장 성장을 가속하고 있습니다. 또한, 주요 시장 기업들은 의약품 안전성 모니터링 업무(PVO)의 아웃소싱과 클라우드 기반 의료 정보 시스템 도입에 주력하고 있습니다. 이는 정확도 최적화, 비용 효율성 향상, 리스크 감소, 전문성 강화, 처리 기간 단축, 조직 민첩성 향상을 목적으로 하며, 시장을 주도할 것으로 예측됩니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 시판 후 약물감시 및 의료 정보 시장
제6장 시장 분석 : 유형별
제7장 시장 분석 : 제품별
제8장 시장 분석 : 최종 사용자별
제9장 시장 분석 : 지역별
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
JHS 26.05.18The global post-marketing pharmacovigilance and medical information market size reached USD 6.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 14.5 Billion by 2034, exhibiting a growth rate (CAGR) of 8.68% during 2026-2034.
Post-marketing pharmacovigilance and medical information is the practice of monitoring the safety and efficacy of drugs and medical devices after their launch. It includes collection, surveillance, and prevention of adverse effects of new medicines, equipment, and therapies. It helps protect patients from unnecessary harm by clarifying risks concerning benefits and refuting false indications. Besides this, it assists researchers in determining required actions throughout the drug formulation cycle. As a result, post-marketing pharmacovigilance and medical information finds a considerable role in the healthcare industry to assess the accuracy of the delivered information between patients and medical professionals. It is also used in research organizations for regulating drug safety guidelines.
POST-MARKETING PHARMACOVIGILANCE AND MEDICAL INFORMATION MARKET TRENDS:
The growing global geriatric population and the rising occurrence of various chronic medical disorders, such as diabetes, hypertension, dementia, cardiovascular diseases, and osteoporosis, represent one of the key factors increasing the consumption of medicines. In addition, the increasing frequency of lifestyle, respiratory and cardiovascular infections, and neurological and oncological diseases are resulting in the increasing sales of drugs worldwide. This, in turn, is creating a positive market outlook. In line with this, the rising prevalence of Adverse Drug Reactions (ADRs), coupled with the incorporation of advanced ADR reporting tools, is supporting the market growth. Apart from this, the expansion of hospitals, clinics, laboratories, and medical research centers is catalyzing the demand for medications and medical devices across the globe. Moreover, governments of various countries are implementing several initiatives to improve healthcare infrastructure and pharmacovigilance services and maintain medical databases, which is strengthening the market growth. Furthermore, leading market players are focusing on outsourcing pharmacovigilance operations (PVO) and introducing cloud-based medical information systems for optimal accuracy, cost efficiency, risk mitigation, domain, improved timelines, and organizational agility, which is anticipated to drive the market.
KEY MARKET SEGMENTATION:
Breakup by Type:
- Spontaneous Reporting
- Intensified ADR Reporting
- Targeted Spontaneous Reporting
- Cohort Event Monitoring
- EHR Mining
Breakup by Product:
- Books
- Online Media
- Journals
Breakup by End User:
- Hospitals
- Research Organization
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Accenture Plc., ArisGlobal, Cognizant Technology Solutions Corporation, Ergomed Plc, F. Hoffmann-La Roche Ltd., Icon Plc, Parexel International Corporation, Pharmaceutical Product Development, Inc. and Wipro Ltd.
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Post-marketing Pharmacovigilance and Medical Information Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Type
- 6.1 Spontaneous Reporting
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Intensified ADR Reporting
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Targeted Spontaneous Reporting
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Cohort Event Monitoring
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 6.5 EHR Mining
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
7 Market Breakup by Product
- 7.1 Books
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Online Media
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Journals
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by End User
- 8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Research Organization
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.1.1 United States
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.2.1 China
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.3.1 Germany
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.4.1 Brazil
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Accenture Plc.
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 ArisGlobal
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.3 Cognizant Technology Solutions Corporation
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.3.4 SWOT Analysis
- 14.3.4 Ergomed Plc
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.5 F. Hoffmann-La Roche Ltd.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 SWOT Analysis
- 14.3.6 Icon Plc
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.6.4 SWOT Analysis
- 14.3.7 Parexel International Corporation
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 SWOT Analysis
- 14.3.8 Pharmaceutical Product Development, Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 SWOT Analysis
- 14.3.9 Wipro Ltd.
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.1 Accenture Plc.
